Literature DB >> 2890683

Clonidine-induced suppression of plasma catecholamines in states of adrenal medulla hyperfunction.

M D Gross1, B Shapiro, J C Sisson, A Zweifler.   

Abstract

To assess adrenal medulla activity in states of hyperfunction, a single 0.3 mg oral dose of clonidine hydrochloride (Catapres) was given to twelve patients with varying evidence of familial adrenal medullary hyperplasia and pheochromocytomas from kindreds with Multiple Endocrine Neoplasia type 2 syndrome (MEN-2), seven patients with sporadic pheochromocytomas and six normal subjects. Mean arterial blood pressure and plasma norepinephrine (NE) levels were lower than baseline values 2 h after clonidine in the normal subjects. Plasma epinephrine (E) rose in one normal but fell in the remainder after clonidine administration. In sporadic pheochromocytoma patients, E fell slightly in 4 and NE fell in 3 while mean arterial blood pressure was not significantly lower than baseline values in 7 patients 2 h after clonidine. In MEN-2, mean arterial blood pressure fell and there was a variable response of plasma E and NE to clonidine, which appears to be related to the presence of detectable anatomic (CT scan) and functional (131I-mlBG scintigraphy) abnormalities of the adrenal medulla. These findings are thus compatible with the spectrum of adrenal medulla dysfunction and the presumed development of pheochromocytoma in this syndrome.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2890683     DOI: 10.1007/BF03348148

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

Review 1.  Drug therapy: clonidine, a new antihypertensive drug.

Authors:  W A Pettinger
Journal:  N Engl J Med       Date:  1975-12-04       Impact factor: 91.245

Review 2.  The role of alpha- and beta-presynaptic receptors in the regulation of noradrenaline release elicited by nerve stimulation.

Authors:  S Z Langer
Journal:  Clin Sci Mol Med Suppl       Date:  1976-12

3.  Adrenal medullary disease in multiple endocrine neoplasia, type 2: pheochromocytoma and its precursors.

Authors:  J A Carney; G W Sizemore; S G Sheps
Journal:  Am J Clin Pathol       Date:  1976-08       Impact factor: 2.493

4.  Different alpha-adrenoreceptors in the central nervous system mediating biochemical and functional effects of clonidine and receptor blocking agents.

Authors:  N E Andén; M Grabowska; U Strömbom
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976       Impact factor: 3.000

5.  Sipple's syndrome: medullary thyroid carcinoma, pheochromocytoma, and parathyroid disease. Studies in a large family. NIH conference.

Authors:  H R Keiser; M A Beaven; J Doppman; S Wells; L M Buja
Journal:  Ann Intern Med       Date:  1973-04       Impact factor: 25.391

6.  Natural history of the familial medullary thyroid carcinoma-pheochromocytoma syndrome and the identification of preneoplastic stages by screening studies: a five-year report.

Authors:  R F Gagel; K E Melvin; A H Tashjian; H H Miller; Z T Feldman; H J Wolfe; R A DeLellis; S Cerviskinner; S Reichlin
Journal:  Trans Assoc Am Physicians       Date:  1975

7.  Effect of clonidine on the function of the adrenal medulla in rats.

Authors:  K Shimamura; H Togashi; H Saito
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1981-01

8.  Scintigraphic localization of phaeochromocytomas.

Authors:  M Fischer; W Vetter; B Winterberg; J Hengstmann; W Zidek; J Friemann; H Vetter
Journal:  Clin Endocrinol (Oxf)       Date:  1984-01       Impact factor: 3.478

9.  Clonidine suppression test for pheochromocytoma: examples of misleading results.

Authors:  H C Taylor; D Mayes; A H Anton
Journal:  J Clin Endocrinol Metab       Date:  1986-07       Impact factor: 5.958

10.  Spectrum of pheochromocytoma in multiple endocrine neoplasia. A scintigraphic portrayal using 131I-metaiodobenzylguanidine.

Authors:  T W Valk; M S Frager; M D Gross; J C Sisson; D M Wieland; D P Swanson; T J Mangner; W H Beierwaltes
Journal:  Ann Intern Med       Date:  1981-06       Impact factor: 25.391

View more
  1 in total

Review 1.  Impact of medications on mIBG uptake, with specific attention to the heart: Comprehensive review of the literature.

Authors:  Arnold F Jacobson; Mark I Travin
Journal:  J Nucl Cardiol       Date:  2015-05-15       Impact factor: 5.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.